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OBJECTIVE — To determine the contribution of maternal glucose and lipids to intrauterine
metabolic environment and fetal growth in pregnancies with gestational diabetes mellitus
(GDM).
RESEARCH DESIGN AND METHODS — In 150 pregnancies, serum triglycerides
(TGs), cholesterol, free fatty acids (FFAs), glycerol, insulin, and glucose were determined in
maternalserumandcordbloodduringthe3rdtrimester.Maternalglucosevaluescamefromoral
glucose tolerance testing and glucose proﬁles. Measurements of fetal abdominal circumference
(AC) were performed simultaneously with maternal blood sampling and birth weight, and BMI
and neonatal fat mass were obtained following delivery.
RESULTS — Maternal TGs and FFAs correlated with fetal AC size (at 28 weeks: triglycerides,
P  0.001; FFAs, P  0.02), and at delivery they correlated with all neonatal anthropometric
measures (FFA: birth weight, P  0.002; BMI, P  0.001; fat mass, P  0.01). After adjustment
for confounding variables, maternal FFAs and TGs at delivery remained the only parameters
independently related to newborns large for gestational age (LGA) (P  0.008 and P  0.04,
respectively).MaternalFFAlevelswerehigherinmotherswithLGAnewbornsthaninthosewith
appropriate for gestational age (AGA) newborns (362.8  101.7 vs. 252.4  10.1, P  0.002).
Maternal levels of TGs, FFAs, and glycerol at delivery correlated with those in cord blood (P 
0.003, P  0.004, and P  0.005, respectively). Fetal triglyceride and cholesterol levels were
negatively correlated with newborn birth weight (P  0.001), BMI (P  0.004), and fat mass
(P  0.001). TGs were signiﬁcantly higher in small for gestational age (SGA) newborns com-
pared with AGA or LGA newborns, while insulin-to-glucose ratio and FFAs were the highest in
LGA newborns.
CONCLUSIONS — In well-controlled GDM pregnancies, maternal lipids are strong predic-
tors for fetal lipids and fetal growth. Infants with abnormal growth seem to be exposed to a
distinct intrauterine environment compared with those with appropriate growth.
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T
here is strong evidential support for
the “fetal origins” hypothesis, which
connects adulthood hypertension,
insulin resistance, and dyslipidemia to
adverse intrauterine conditions during
gestation that might be associated with
disproportionate fetal growth. An in-
creased risk for adult metabolic disorders
is well documented for subjects born
growthretarded(1).Inaddition,thereare
substantial data indicating that acceler-
ated fetal growth predisposes to later
obesity (2), especially in diabetic preg-
nancies (3). Therefore, normalization of
fetal growth is a principle in the man-
agement of pregnancies with diabetes.
Therapeutic strategies that focus on
tight glucose control have often limited
success in avoiding accelerated growth
and may even result in growth restric-
tion. In overweight pregnant women,
fetal growth seems to be determined
only to a small extent by maternal glu-
cose values (4), and normalization of
fetal growth may only be achieved by
the addition of insulin therapy despite
apparently good glucose control with
diet (5).
In view of increasing evidence that
obesity, diabetes and cardiovascular
diseases in later life may have prenatal
antecedents, investigation of the deter-
minants of intrauterine environment
andfetalgrowthhavebecomeanimpor-
tant area of research. Variation of birth
weight is strongly determined by neo-
natal fat mass, and it is likely that fetal
growth disorders might also result from
variations in maternal and fetal lipid
metabolism. In nondiabetic pregnan-
cies, maternal triglycerides (TGs) have
been shown to be correlated with birth
weight (6–9).
Our study aimed to determine the
potential relationship of maternal se-
rum glucose and lipids to intrauterine
metabolic environment and fetal
growth during late pregnancy in well-
controlled gestational diabetic women.
Therefore, we investigated the correla-
tion of maternal serum lipid and glu-
cose parameters, measured at different
time points in the 3rd trimester of preg-
nancy, with fetal and neonatal anthro-
pometric parameters and with the
correspondent parameters in cord
blood representing the current intra-
uterine metabolic environment of new-
borns that are small (SGA), appropriate
(AGA), and large for gestational age
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gestational diabetes mellitus (GDM).
RESEARCH DESIGN AND
METHODS—The study population
was derived from a prior intervention
study that compared different manage-
ment strategies in GDM (10). All women
had GDM diagnosed based on a 75-g oral
glucosetolerancetest(OGTT)withdeter-
mination of three glucose values in capil-
lary blood using the hexokinase method;
at least two values had to exceed the Car-
penter & Coustan criteria, which are en-
dorsed by the American Diabetes
Association (95/180/155 mg/dl) for mea-
surements in venous plasma. With re-
specttolowerglucoseconcentrationsin
capillary compared with venous blood,
the threshold for fasting glucose was
modiﬁed into 90 mg/dl, while postchal-
lenge capillary glucose levels corre-
spond with those in venous blood (11).
The women were given dietary instruc-
tion and performed self-monitoring of
blood glucose. Additional insulin ther-
apy was given either based principally
on maternal glucose levels or on fetal
growth, as described previously (10).
Data regarding maternal and neonatal
characteristics, maternal glucose values
from the diagnostic OGTT, and mean
fasting and postprandial values from
glucose proﬁles measured twice weekly
were extracted from the database of the
primary study.
Maternal blood samples were sched-
uled to be taken at entry to the study
(28 weeks of gestation) and at 32, 36,
and 39 weeks. Serum samples were fro-
zen and stored at 80°C until analysis.
Cord blood samples were taken immedi-
ately following delivery, and serum was
stored at 80°C. Insulin was determined
by ELISA (Pharmacia, Uppsala, Sweden);
TGs, free fatty acids (FFAs), and choles-
terol were measured by commercial kits
(Menarini Diagnostic, Florence, Italy, for
TGs and cholesterol; and Wako Chemi-
cal, Neuss, Germany, for FFAs). Glycerol
was determined using a ﬂuorometric
method.
Fetal growth was measured by ul-
trasound performed at the same time as
the maternal blood sampling. For anal-
ysis, we focused on abdominal circum-
ference (AC), since the growth
differences of the AC are mainly deter-
mined by the thickness of insulin-
sensitive subcutaneous fat. Birth weight
and length were obtained shortly after
delivery, and neonatal skinfold thick-
ness at the ﬂank was measured within
48 h. Neonatal fat mass was calculated
by a formula derived from Catalano et
al. (12) that includes birth weight and
length and ﬂank skinfolds measure-
ment: 0.30055 (birth weight)  0.0453
(ﬂank skinfold) – 0.03237 (length) 
0.54657. Correlation with fat mass val-
ues obtained by total body electric con-
ductivity, which is considered the gold
standard, has been reported to be very
high (R
2  0.78, P  0.001) (12). In-
fants with birth weight 10th percen-
tile were classiﬁed as SGA, and those
with birth weight 90th percentile as
LGA based on gestational age and sex-
Table 1—Maternal and neonatal characteristics of pregnancies with GDM
Maternal characteristics
Age (years) 31.2  4.9
Parity 2.05  1.2
Prepregnancy BMI (kg/m
2) 27.8  6.2
Gestational age at diagnosis (weeks) 25.9  4.4
Gestational age at entry (weeks) 28.3  2.4
OGTT fasting (mg/dl) 94.3  13.9
1 h 202.3  26.9
2 h 158.3  31.8
Glucose proﬁles at entry (mg/dl)
Mean fasting glucose 87.9  10.9
Mean postprandial glucose 113.5  15.3
Glucose proﬁles close to delivery (mg/dl)
Mean fasting glucose 83.5  10.7
Mean postprandial glucose 109.2  13.7
Neonatal characteristics
Gestational age at delivery (weeks) 39.2  1.4
Birth weight (g) 3,389.81  503
BMI (kg/m
2) 13.0  1.3
Fat mass (g) 432.1  162.6
LGA (%) 13.1
SGA (%) 12.9
C-section rate (%) 11.7
Data are means  SD.
Table 2—Metabolic parameters in maternal serum close to delivery and in cord blood of all the offspring and according to categories of SGA,
AGA, and LGA newborns from mothers with GDM
Mother
Offspring
Total SGA AGA LGA
n 150 20 111 19
Glucose (mg/dl) 84.2  18.3 85.0  21.4 82.6  28.6
a 86.0  21.0
a 80.3  13.7
a
Insulin (U/ml) 25.2  21.7* 10.2  6.25 8.1  10.0
a 8.6  5.3
a 20.8  6.9
b
Insulin-to-glucose ratio 0.29  0.21† 0.07  0.002 0.06  0.01
a 0.03  0.005
a 0.26  0.08
b
TGs (mg/dl) 265.9  87.6† 41.6  21.8 62.1  27.5
a 40.3  22.6
b 32.0  17.5
b
Cholesterol (mg/dl) 253.7  55.6† 63.5  17.7 64.5  14.4
a 63.3  18.7
a 63.5  12.4
a
Glycerol (mol/l) 202.4  100.3† 76.1  64.2 107.4  123
a 70.5  54.0
a 101.5  83.2
a
FFAs (mol/l) 262.5  112.4† 146.3  88.2 189.0  78.0
a,b 135.2  75.8
a 213.0  149.8
b
DataaremeansSE.Forthedifferencebetweenmaternalserumandcordblood(totaloffspring):*P0.05and†P0.001.ForthedifferencebetweenSGA,AGA,
and LGA newborns: different superscript letters indicate P  0.05.
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rived from a German national database
(13).
Data management and analysis was
performedusingSPSS12.0(Chicago,IL).
Results are expressed as means  SD. Re-
lationships between variables were ana-
lyzed by bivariate correlation applying
Spearman’s correlation test. Differences
between groups were analyzed using
ANOVA with Bonferroni adjustment.
Multiple logistic regression analysis was
performed to determine maternal param-
eters independently associated with birth
weight. All statistical tests were two-
tailed, and a P value 0.05 was consid-
ered signiﬁcant.
RESULTS—From the original study
population (10), 150 mother-newborn
pairswereselectedbasedonavailabilityof
complete maternal blood and cord blood
samples. Maternal and neonatal charac-
teristics are shown in Table 1, and meta-
bolic parameters measured in maternal
blood taken close to delivery (between 36
and39weeksofgestation,inmostcases1
week to delivery) and in cord blood are
showninTable2.The remainingwomen
from the primary study who could not
be included in the presented study due
to missing cord blood samples were not
signiﬁcantly different from the women
included regarding maternal or new-
born characteristics.
Except for glucose, the concentration
ofallparametersdeterminedinthemoth-
ers’serumwassigniﬁcantlyhigherthanin
the correspondent cord blood serum.
When all the individual paired samples
were compared, only maternal levels of
TGs, FFAs (Fig. 1), and glycerol taken
close to delivery correlated signiﬁcantly
with those in cord blood (r  0.19, P 
0.003;r0.28,P0.004;r0.26,P
0.005, respectively). The relationship be-
tween the different maternal metabolic
parameters during the 3rd trimester and
fetal growth was evaluated by their corre-
lation with the fetal AC measured at entry
to the study (28.3  2.4 weeks of gesta-
tion) and at 32 and 36 weeks. Both ma-
ternal TGs and FFAs correlated positively
andsigniﬁcantlywithfetalACsizeateach
ofthestudiedtimepoints(entry:TGs,r
0.26, P  0.001; FFAs, see Fig. 1). How-
ever, there were no signiﬁcant correla-
tions between fetal growth and any
maternal glucose values either from the
OGTT or from the self-monitoring glu-
Figure 1—Correlation of maternal serum FFA with fetal growth and
fetal FFA. A: Maternal FFA at study entry, 28 weeks of gestation,
and fetal abdominal circumference at study entry. B: Maternal FFA
close to delivery and neonatal fat mass. C: Maternal FFA close to
delivery and fetal FFA measured in cord blood serum.
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32 and 36 weeks (data not shown). Ma-
ternal parameters from blood samples
taken close to delivery were compared
with neonatal anthropometric mea-
sures. Maternal plasma FFA and glyc-
erol levels were signiﬁcantly related to
all anthropometric measures of new-
borns (glycerol vs. birth weight: r 
0.23, P  0.3, vs. BMI: r  0.24, P 
0.006,andvs.fatmass:r0.23,P0.01;
for FFAs vs. birth weight: r  0.27, P 
0.002, vs. BMI: r  0.3, P  0.001, and
vs. fat mass: see Fig. 1). Maternal TGs
had a positive correlation with newborn
fat mass (r  0.17, P  0.03) but not
withbirthweightorneonatalBMI.After
adjustment for maternal prepregnancy
BMI, weight gain, age, parity, fasting,
and postprandial glucose from the pro-
ﬁles at 36 weeks and close to delivery,
only maternal FFAs and TGs remained
independently related to LGA (adjusted
P  0.008 and P  0.04, respectively).
Maternal FFA levels were signiﬁcantly
higher in mothers with LGA infants
than in mothers with AGA infants
(362.8  101.7 vs. 252.4  10.1
mol/l, P  0.002).
On the neonate side, cord TG and
cholesterol levels correlated negatively
and signiﬁcantly with birth weight (Fig.
2), BMI (r  0.24, P  0.004), and fat
mass (Fig. 2), whereas insulin and the in-
sulin-to-glucose ratio correlated posi-
tively and signiﬁcantly with birth weight
(r  0.23, P  0.006, and r  0.19, P 
0.03, respectively), BMI (r  0.24, P 
0.005, and r  0.21, P  0.12), and fat
mass (r  0.21, P  0.02; and r  0.17,
P  0.48). Cord blood glucose, glycerol,
and FFAs did not show any signiﬁcant
correlation with neonatal size. Cord
blood TG levels of SGA newborns were
signiﬁcantly increased compared with
thoseofAGAorLGAnewborns(Table2),
whereas insulin, insulin-to-glucose ratio,
andFFAswerethehighestinLGAinfants.
CONCLUSIONS —The present ﬁnd-
ings demonstrate that circulating mater-
Figure 2—Correlation of cord blood serum TGs and cholesterol with birth weight and neonatal fat mass.
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fetal growth at different time points dur-
ing the 3rd trimester in a population of
well-controlled GDM pregnancies. Ma-
ternal FFAs and TG levels measured close
todeliverypredictedLGAbirthweightin-
dependently of maternal BMI, and mater-
nal FFA, TG, and glycerol concentrations
correlated with those measured in cord
blood serum. Cord blood of SGA new-
borns showed high TG levels, whereas
LGAnewbornsshowedhighFFAconcen-
trations, high insulin-to-glucose ratios,
and low TG levels.
BothmaternalTGandFFAlevelscor-
related with fetal growth during preg-
nancy and with neonatal anthropometric
measures, the best correlation found with
neonatal fat mass. Maternal hypertriglyc-
eridemia is a characteristic feature of
pregnancy (14), and although maternal
circulating TGs do not directly cross the
placenta (15), the presence of lipoprotein
receptors, fatty acid–binding proteins
(16), and different lipase activities (17) in
theplacentaallowstheefﬁcienttransferof
maternal fatty acids to the fetus. It had
been previously shown that the concen-
tration of TGs in the 3rd trimester is a
stronger predictor of birth weight than
glucoseparameters(6–8).Publisheddata
have been limited to a one–time point
measurementinconjunctionwithOGTT,
whereas this study considers lipid and
glucose data at different times during the
3rd trimester and close to delivery (1
week to delivery). Due to the strict pri-
mary protocol of the investigated study
cohort, our study population presented a
tight and stable glucose control, which
may have attenuated the impact of varia-
tions in maternal glycemia on fetal
growth. However, even at study entry,
glucose values were not related to fetal
growth, and from clinical experience we
know that good glucose control does not
necessarily prevent accelerated growth,
especiallyinobesewomen.Thesuccessof
additional insulin therapy to lower the
macrosomia rate in obese women with
normal glucose values, as demonstrated
by Langer et al. (5), may be in part the
result of the antilipolytic effect of insulin.
This action would decrease maternal FFA
and TG levels, reducing their potential ef-
fectonfetalfatmass.Thismayexplainthe
normalization of macrosomia rates ob-
served in studies that applied a fetal
growth–based approach of individual-
ized GDM therapy. Insulin therapy was
given to women with accelerated fetal
growth, as indicated by fetal AC 75th
percentile despite maternal glucose being
maintained within the target range
(10,18). Our ﬁndings are in accordance
with those of Kitijama et al. and Knopp et
al. (6,7), who showed that high maternal
TGlevelspredictedmacrosomiaindepen-
dently of maternal BMI.
The potential importance of maternal
lipids for the development of the fetus is
underlined by the fact that both cord
blood FFA and TG levels seemed to be
tightly associated with maternal lipids.
There is a paucity of studies published
thus far comparing maternal and fetal
lipid parameters. In contrast to our data
obtained in a well-controlled GDM pop-
ulation, Merzouk et al. (19) reported that
maternal triglyceride levels in late gesta-
tion had been a signiﬁcant predictor of
elevated fetal lipids only in a group of
poorlycontrolleddiabeticmothers,notin
well-controlled type 1 diabetic mothers.
In another study, the same authors re-
ported corresponding lipoprotein abnor-
malities (elevated TGs, cholesterol, and
apolipoprotein B100) only in obese
mothers and their macrosomic infants
(20).
The most striking ﬁnding from this
study was that fetal TGs were negatively
correlated with birth weight, resulting in
signiﬁcantly higher TG levels in SGA
newborns compared with AGA or LGA
infants. There are previous studies dem-
onstrating elevated TG levels in cord
blood of growth retarded newborns
(21,22). A theoretical explanation for the
inverse correlation between fetal TGs and
birth weight might be reduced lipopro-
tein lipase (LPL) activity. LPL present in
the capillary endothelium of extrahepatic
tissuescatalyzesthehydrolysisofTG-rich
lipoproteins (namely chylomicrons and
VLDL) and their products, and FFAs and
glycerol are taken up by the adjacent tis-
sue. Because it is known that the expres-
sion of LPL is strongly associated with the
development of adipose tissue, we hy-
pothesize that SGA newborns might have
a low LPL activity responsible for their
augmented circulating TG levels. By con-
trast, low TG levels found in LGA new-
borns would be the result of enhanced
LPL activity derived from their increased
adipose mass. Interestingly, in the pediat-
ric literature there are also reports of high
TG levels in the serum of SGA newborns
taken a few days after delivery (23,24),
especiallyininfantswithaPonderalindex
10th percentile (24). This ﬁts with our
observations and suggests that SGA in-
fants appear to have impaired utilization
of circulating TGs, as a consequence of
lacking peripheral adipose.
In relation to the question of whether
infants with abnormalities in growth are
exposed to a different intrauterine envi-
ronment than those with appropriate
growth, our data demonstrated that both
newborns with impaired or accelerated
growthshowmetabolicabnormalitiesbut
of different character. SGA newborns had
been exposed to high levels of TGs,
whereas LGA infants already showed in-
trauterine signs of insulin resistance indi-
catedbythehighinsulin-to-glucoseratio.
This could be responsible for the elevated
FFA levels found in the LGA infants,
which might reﬂect a reduced effect of
insulin inhibiting lipolysis or augmented
lipolyticactivityduetotheirincreasedad-
ipose tissue mass. How these metabolic
patternscontributetotheknowndisposi-
tion of SGA and LGA newborns for obe-
sity, diabetes, and cardiovascular
disorders in later life remains to be exam-
ined further. From animal models, we
know that induced hyperinsulinism in
the area of the hypothalamus region dur-
ing the perinatal phase leads to later obe-
sity. Little is known about the long-term
effects of intrauterine hypertriglyceride-
mia. We do know that blood lipoprotein
abnormalities in childhood are predictive
forthoseinadulthood(25),anditislikely
that this is also true extremely early
in life, a very sensitive time. In summary,
these ﬁndings show the effect of a
disturbed maternal lipid metabolism on
the fetal metabolic environmental and fe-
tal growth that may have long-term
consequences.
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